Topics:

HER2-Positive Breast Cancer

CLEOPATRA: Pertuzumab Ups Survival by 16 Months in HER2-Positive Breast Cancer

Data from the CLEOPATRA trial show that pertuzumab adds nearly 16 months to median survival times when used with trastuzumab and chemo in HER2-positive breast cancer, according to final results presented at the ESMO 2014 Congress.

HER2-Positive Breast Cancer

The level of stromal tumor-infiltrating lymphocytes (Str-TILs) may influence which treatment is the most effective in women with HER2-positive breast cancer.

Data from the CLEOPATRA trial show that pertuzumab adds nearly 16 months to median survival times when used with trastuzumab and chemo in HER2-positive breast cancer, according to final results presented at the ESMO 2014 Congress.

HER2-positive breast cancer patients treated with targeted therapy and chemo were less likely to have a pathologic complete response if they had a PIK3CA mutation.

In this video, Dr. Sledge discusses what the negative results of the ALTTO trial mean for women with HER2-positive breast cancer.

An 8-year follow-up of HER2-positive breast cancer patients receiving adjuvant trastuzumab shows an overall low incidence of cardiac events when administered after chemotherapy and radiotherapy.

After surgery, adjuvant therapy with trastuzumab alone works just as well as trastuzumab combined with lapatinib for women with early-stage HER2-positive breast cancer.

A follow-up analysis of gene expression signatures from the CALGB 40601 trial shows that certain HER2-positive early-stage breast cancer patients may not benefit from more aggressive chemotherapy treatments as part of a neoadjuvant regimen, and that patients with HER2-enriched tumors responded best to dual anti-HER2 treatment.

Pages

Subscribe to HER2-Positive Breast Cancer on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.